OverviewSuggest Edit

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies. The Company's pipeline is comprised of cell-based therapies for cancer and immune disorders. Its cellular immunotherapies are based on ex vivo cell programming approach to modulate the therapeutic function and direct the fate of hematopoietic cells.

TypePublic
Founded2007
HQSan Diego, US
Websitefatetherapeutics.com
Employee Ratings4.2

Latest Updates

Employees (est.) (Dec 2019)178(+72%)
Job Openings37
Revenue (FY, 2019)$10.7 M(+126%)
Share Price (Oct 2020)$47.5 (-2%)
Cybersecurity ratingCMore

Key People/Management at Fate Therapeutics

Scott Wolchko

Scott Wolchko

President & CEO, Director
William Rastetter

William Rastetter

Chairman
Dan Shoemaker

Dan Shoemaker

Chief Scientific Officer
John Mendlein

John Mendlein

Vice Chairman
Edward Dulac

Edward Dulac

Chief Financial Officer
Bob Valamehr

Bob Valamehr

Chief Development Officer
Show more

Fate Therapeutics Office Locations

Fate Therapeutics has an office in San Diego
San Diego, US (HQ)
3535 General Atomics Ct
Show all (1)

Fate Therapeutics Financials and Metrics

Fate Therapeutics Revenue

Fate Therapeutics's revenue was reported to be $10.68 m in FY, 2019
USD

Revenue (Q2, 2020)

5.5m

Net income (Q2, 2020)

(28.1m)

EBIT (Q2, 2020)

(28.7m)

Market capitalization (19-Oct-2020)

4.1b

Closing stock price (19-Oct-2020)

47.5

Cash (30-Jun-2020)

433.1m

EV

3.8b
Fate Therapeutics's current market capitalization is $4.1 b.
Annual
USDFY, 2013FY, 2014Y, 2014FY, 2015Y, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

971.0k971.0k2.4m2.4m4.4m4.1m4.7m10.7m

Revenue growth, %

(81%)150%

General and administrative expense

6.6m8.5m10.4m9.9m11.9m15.8m23.6m

R&D expense

12.0m16.4m19.9m26.5m34.4m56.0m87.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

209.0k329.0k1.0m1.3m1.0m1.0m1.0m1.0m1.0m1.0m1.0m1.0m2.6m2.8m2.4m2.5m5.5m

General and administrative expense

2.0m2.4m2.1m1.9m2.8m2.7m2.4m2.6m2.2m2.6m3.0m2.7m2.8m3.6m3.8m4.1m5.4m5.3m6.3m7.7m7.5m

R&D expense

3.4m4.5m4.0m4.1m4.6m4.9m5.0m6.6m6.8m6.8m8.0m7.9m8.6m11.5m16.8m13.6m17.7m21.6m23.2m29.3m26.7m

Operating expense total

5.4m6.9m6.0m6.0m7.3m7.5m7.4m9.2m9.0m9.4m11.0m10.6m11.4m15.1m20.6m17.7m23.1m26.9m29.5m37.0m34.2m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

54.0m49.1m64.8m88.6m89.0m190.5m99.8m

Accounts Receivable

500.0k

Prepaid Expenses

615.0k771.0k843.0k1.6m3.7m5.7m

Inventories

1.2m
USDQ3, 2013

Financial Leverage

-0.3 x
Show all financial metrics

Fate Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

C

72/100

SecurityScorecard logo

Fate Therapeutics Online and Social Media Presence

Embed Graph

Fate Therapeutics News and Updates

Fate Therapeutics Presents its First Off-the-shelf, iPSC-derived CAR T-Cell Cancer Immunotherapy Program at ASH Annual Meeting

FT819 Exhibits Enhanced Tumor Clearance In Vivo Compared to Primary CAR T Cells in Preclinical Leukemia Model

Fate Therapeutics Announces Clinical Data from Landmark Phase 1 Studies of First-ever Universal, Off-the-shelf, iPSC-derived NK Cell Cancer Immunotherapy Programs

No Morphologic Evidence of Leukemia and Complete Neutrophil Recovery Observed in First Patient Treated with FT516 Monotherapy for AML following First Dosing Cycle

Fate Therapeutics Announces Completion of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

The Life Sciences team advised Fate Therapeutics on the closing of its public offering of 9,890,000 shares of its common stock, which included 1,290,000 shares that were issued pursuant to the full exercise of the underwriters’ option to purchase additional shares.read more

Fate Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress

First Patient Treated with FT500 Off-the-Shelf NK Cell Cancer Immunotherapy in Landmark Clinical Trial

Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2018 Financial Results

SAN DIEGO, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the Company will host a conference call and live…

Fate Therapeutics stock up 11% after FDA clears IND application

Shares of Fate Therapeutics Inc. were up 11% in premarket trade Wednesday after the company announced that the FDA had cleared its investigational new drug application for FT516, a potential therapy for patients with certain blood cancers. FT516 is a natural killer cell product engineered to make a…
Show more

Fate Therapeutics Blogs

413AW, Scientist/ Associate Scientist, Cancer Immunotherapy (Stealth)

Job Code 413AW Description Fate Therapeutics is seeking a highly motivated individual with expertise in cancer immunology and allogeneic adoptive cell transfer biology or related fields to join a multidisciplinary team dedicated to the discovery of novel cellular therapeutics for the treatment of ca…

412AG, Senior Scientist / Scientist, Cancer Immunotherapy (Solid Tumor)

Job Code 412AG Description Fate Therapeutics is in search of a talented and motivated individual to become part of our NK cell cancer immunotherapy team. Our rapidly growing team is part of a great effort to develop allogeneic, off-the-shelf adoptive cell therapy products. Paramount to this position…

411JH, Associate Scientist, Molecular Engineering

Job Code 411JH Description Fate Therapeutics is seeking a talented and highly motivated individual skilled in molecular biology that will be a key member of the Molecular Engineering team. The primary functions of this role will include DNA and RNA extraction, traditional PCR, gel electrophoresis, q…

410SM, Data Integration Engineer

Job Code 410SM Description Fate Therapeutics is seeking an experienced Data Integration Engineer with biotechnology domain experience to deploy specialized integrations within a complex regulated environment across all Company business units. The successful candidate will manage the Integration from…

409GDB, Manager, Materials Management

Job Code 409GDB Description Fate Therapeutics is currently seeking a motivated individual to support raw material management at Fate’s manufacturing facility. The successful candidate is an excellent communicator, with strong attention to detail and problem-solving skills and has in-depth knowledge …

408HY, Director / Associate Director, Data Science

Job Code 408HY Description Fate Therapeutics is seeking a highly skilled and motivated statistician to serve as a data science lead in our Biometrics Group. This individual will provide statistical oversight and expertise across a broad range of non-clinical areas, including drug discovery, pre-clin…
Show more

Fate Therapeutics Frequently Asked Questions

  • When was Fate Therapeutics founded?

    Fate Therapeutics was founded in 2007.

  • Who are Fate Therapeutics key executives?

    Fate Therapeutics's key executives are Scott Wolchko, William Rastetter and Dan Shoemaker.

  • How many employees does Fate Therapeutics have?

    Fate Therapeutics has 178 employees.

  • What is Fate Therapeutics revenue?

    Latest Fate Therapeutics annual revenue is $10.7 m.

  • What is Fate Therapeutics revenue per employee?

    Latest Fate Therapeutics revenue per employee is $60 k.

  • Who are Fate Therapeutics competitors?

    Competitors of Fate Therapeutics include Genewiz, LGC and NovaBay Pharmaceuticals.

  • Where is Fate Therapeutics headquarters?

    Fate Therapeutics headquarters is located at 3535 General Atomics Ct, San Diego.

  • Where are Fate Therapeutics offices?

    Fate Therapeutics has an office in San Diego.

  • How many offices does Fate Therapeutics have?

    Fate Therapeutics has 1 office.